Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
US9125835B2 · kind B2 · utility
1Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2011 |
| Grant date | Sep 8, 2015 |
| Priority date | — |
| Expiry date | Jan 8, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08L2203/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.